A Phase 1/2 interventional study of cell therapy, bone marrow derived stem cell in Acute Myocardial Infarction, sponsored by Azienda Unita Sanitaria Locale di Piacenza. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-03-24.
Sponsored by Azienda Unita Sanitaria Locale di Piacenza · Phase 1/2, Interventional, and Treatment
We will study in a prospective randomised fashion 50 patients who will be treated by intracoronary transplantation of autologous, mononuclear bone marrow cells (BMCs) in addition to standard therapy after MI or standard therapy.
After standard therapy for acute MI, 10 patients were transplanted with autologous mononuclear BMCs via a balloon catheter placed into the infarct-related artery during balloon dilatation (percutaneous transluminal coronary angioplasty). Another 10 patients with acute MI were treated by standard therapy alone. After
Experimental and clinical data suggest that bone marrow-derived cells may contribute to the healing of myocardial infarction (MI).
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's planned enrollment of 50 is below the median of 148 across 1,595 interventional studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →Azienda Unita Sanitaria Locale di Piacenza is the lead sponsor of 15 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Mortality
Mortality and Morbidity
Left ventricular function
Left ventricular remodeling
Heart rate variability
Baroreflex sensitivity
Stress induced myocardial ischemia
Cell dose response
This study is status unknown, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Unita Sanitaria Locale di Piacenza